1515. Nationwide trends of invasive pneumococcal disease in Spain for the period 2009-2019 | Zendy

Sara de Miguel | Zendy; Mirian Domenech | Zendy; Julio Sempere | Zendy; Fernando GonzálezCamacho | Zendy; José Yuste | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

1515. Nationwide trends of invasive pneumococcal disease in Spain for the period 2009-2019

Author(s) -

Sara de Miguel,

Mirian Domenech,

Julio Sempere,

Fernando GonzálezCamacho,

José Yuste

Publication year - 2020

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofaa439.1696

Subject(s) - serotype , medicine , pneumococcal disease , streptococcus pneumoniae , pneumococcal conjugate vaccine , pediatrics , pneumococcal polysaccharide vaccine , population , disease control , conjugate vaccine , virology , immunology , immunization , environmental health , antibiotics , microbiology and biotechnology , antigen , biology

Background Introduction of pneumococcal conjugate vaccines (PCV) is an effective measure to control the invasive pneumococcal disease (IPD) although the emergence of non-vaccine serotypes is of great concern worldwide. Methods This study includes national data from IPD cases affecting pediatric and adult population for the period (2009-2019). Data contain 25341 laboratory-confirmed clinical isolates of Streptococcus pneumoniae causing IPD in Spain. Results The overall reduction of IPD cases by serotypes included in PCV13 was 88% for children and 67% in adults with a constant increase of IPD cases by serotype 8 in adults since 2015. In children, serotypes 24F (12%), 8 (10%) and 3 (9%) were the most frequent in 2019 whereas in adults, serotypes 3 and 8 accounted for 37% of IPD cases. IPD cases in adults by additional serotypes covered by the 23-valent polysaccharide vaccine (PPV23) have risen constantly within the years, increasing from 19% in 2009 to 52% in 2019. IPD cases by Non-vaccine types in adults (not covered by PCV13 or PPV23) show a moderate increase from 14% in 2009 to 24% in 2019. Conclusion Emerging serotypes are observed in Spain with the rise of serotype 24F in children and 8 in adults as a worrisome event. Disclosures Jose Yuste, n/a, GSK (Consultant)MSD (Consultant, Research Grant or Support)Pfizer (Consultant)

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research